Literature DB >> 11557915

The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men.

V Dishy1, G Sofowora, P A Harris, M Kandcer, F Zhan, A J Wood, C M Stein.   

Abstract

BACKGROUND: Sildenafil, a treatment for erectile dysfunction, is a specific phosphodiesterase type 5 (PDE 5) inhibitor that enhances nitric oxide (NO)-mediated vasodilation in the corpus cavernosum by inhibiting cyclic guanosine monophosphate breakdown. Since PDE 5 is widely expressed in the vasculature, we examined the hypothesis that sildenafil could enhance NO-mediated vasodilation in other vascular beds and improve endothelial function.
METHODS: NO-mediated responses to acetylcholine (endothelium-dependent) and nitroglycerin (endothelium-independent) were measured in healthy men in the dorsal hand vein (n = 13), after the administration of either sildenafil 50 mg or placebo. Flow-mediated dilation of the brachial artery and forearm postischemic reactive hyperemia were measured before and after sildenafil 50 mg, isosorbide dinitrate 5 mg, and placebo in a double-blind, randomized, crossover study (n = 11).
RESULTS: In the hand vein, sildenafil administration increased sensitivity to local nitroglycerin. The 50% effective dose decreased approximately 4-fold from 13.5 ng/min (range, 6.9-26.6 ng/min) to 2.7 ng/min (range, 1.1-6.4 ng/min) (P =.025). Sildenafil decreased the maximum venoconstriction induced by phenylephrine from 81% +/- 3% to 74% +/- 3% (P =.025). Sildenafil did not significantly affect the maximal venodilatory response to acetylcholine (35% +/- 7% after placebo versus 32% +/- 8% after sildenafil) (P =.7). In the arterial vasculature, flow-mediated dilation before (2.4% +/- 1%) and after (2.8% +/- 1.4%) sildenafil (P =.8) and postischemic reactive hyperemia area under the curve before (1807 +/- 393 mL. min. s/100 mL) and after (1467 +/- 257 mL. min. s/100 mL) sildenafil were not different (P =.8). Resting heart rate, blood pressure, and resting brachial artery diameter were unchanged after sildenafil administration. Isosorbide dinitrate, an endothelium-independent vasodilator, caused a significant increase in resting brachial artery diameter from 0.53 +/- 0.01 cm to 0.56 +/- 0.02 cm (P =.005), without altering flow-mediated dilation.
CONCLUSIONS: In healthy men sildenafil increased sensitivity to nitroglycerin, an exogenous NO donor, approximately 4-fold but did not affect endothelium-dependent, NO-mediated responses in either the hand vein or forearm vasculature. Differential vascular responses to sildenafil may localize its enhancement of endogenous NO-mediated vasodilation to vascular beds such as the corpus cavernosum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557915     DOI: 10.1067/mcp.2001.117995

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

2.  A standalone perfusion platform for drug testing and target validation in micro-vessel networks.

Authors:  Boyang Zhang; Carlotta Peticone; Shashi K Murthy; Milica Radisic
Journal:  Biomicrofluidics       Date:  2013-08-26       Impact factor: 2.800

3.  The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.

Authors:  Bart J Van der Schueren; Rebecca Blanchard; M Gail Murphy; John Palcza; Inge De Lepeleire; Anne Van Hecken; Marleen Depré; Jan N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans.

Authors:  Jacqueline K Limberg; Katherine R Malterer; J Mikhail Kellawan; William G Schrage; Brad W Wilkins; Wayne T Nicholson; John H Eisenach; Michael J Joyner; Timothy B Curry
Journal:  Eur J Appl Physiol       Date:  2016-12-24       Impact factor: 3.078

5.  Sildenafil increases sympathetically mediated vascular tone in humans.

Authors:  John M Dopp; Alexei V Agapitov; Christine A Sinkey; William G Haynes; Bradley G Phillips
Journal:  Am J Hypertens       Date:  2013-02-26       Impact factor: 2.689

Review 6.  Phosphodiesterase 5 inhibition in essential hypertension.

Authors:  Lorenzo Ghiadoni; Daniele Versari; Stefano Taddei
Journal:  Curr Hypertens Rep       Date:  2008-02       Impact factor: 5.369

7.  Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers.

Authors:  Victor Dishy; Paul A Harris; Rosanna Pierce; Harish C Prasad; Gbenga Sofowora; Holly L Bonar; Alastair J J Wood; C Michael Stein
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

8.  Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures.

Authors:  Christina Ross; Karol Szczepanek; Maxwell Lee; Howard Yang; Cody J Peer; Jessica Kindrick; Priya Shankarappa; Zhi-Wei Lin; Jack D Sanford; William D Figg; Kent W Hunter
Journal:  Mol Cancer Res       Date:  2020-06-08       Impact factor: 5.852

9.  Phosphodiesterase-5 inhibition preserves exercise-onset vasodilator kinetics when NOS activity is reduced.

Authors:  J Mikhail Kellawan; Jacqueline K Limberg; Zachariah M Scruggs; Wayne T Nicholson; William G Schrage; Michael J Joyner; Timothy B Curry
Journal:  J Appl Physiol (1985)       Date:  2017-10-05

Review 10.  Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.

Authors:  Giovanni Vanni Frajese; Flavio Pozzi; Gaetano Frajese
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.